Acceleron Pharma (XLRN) Misses Q4 EPS by 14c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Acceleron Reports Fourth Quarter and Full Year 2019 Operating and Financial Results
February 27, 2020 4:05 PM EST- REBLOZYL® (luspatercept-aamt), a first-in-class erythroid maturation agent, was approved by the U.S. FDA for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions; FDA review of the sBLA for the lower-risk myelodysplastic syndromes indication is ongoing -
- Multiple clinical presentations reviewed at the 61st American Society of Hematology (ASH) Annual Meeting; MEDALIST trial results published in New England Journal of Medicine -
- The PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH) achieved... More
